Abstract
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Leopold W. R., Shillis J. L., Mertus A. E., Nelson J. M., Roberts B. J., Jackson R. C. Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues. Cancer Res. 1984 May;44(5):1928–1932. [PubMed] [Google Scholar]
- Roberts B. J., Hamelehle K. L., Sebolt J. S., Leopold W. R. In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol. 1986;16(2):95–101. doi: 10.1007/BF00256156. [DOI] [PubMed] [Google Scholar]
- Tunac J. B., Graham B. D., Dobson W. E., Lenzini M. D. Novel antitumor antibiotics, CI-940 (PD 114,720) and PD 114,721. Taxonomy, fermentation and biological activity. J Antibiot (Tokyo) 1985 Apr;38(4):460–465. doi: 10.7164/antibiotics.38.460. [DOI] [PubMed] [Google Scholar]